Browsing Tag
Merck
108 posts
How Merck’s Keytruda became a global immunotherapy benchmark in cancer treatment
Explore Keytruda’s journey from early PD-1 research to global immunotherapy dominance, with clinical, regulatory, and innovation context shaping cancer care in 2025.
Innovent Biologics secures FDA greenlight for first global Phase 3 trial of IBI363 in lung cancer
Innovent Biologics wins FDA approval for its first global Phase 3 trial of IBI363 in lung cancer, signaling a major milestone in immuno-oncology.
Skyhawk Therapeutics and Merck sign $2bn RNA drug discovery pact targeting neurological disorders
Skyhawk Therapeutics inks $2B Merck deal to develop RNA-targeted neurology drugs, highlighting splicing modulation as a new frontier.
What makes Ohtuvayre different from Spiriva or Trelegy? Inside the science of dual inhibition
How is Ohtuvayre different from Spiriva and Trelegy? Discover why Merck’s dual PDE3/PDE4 inhibition could change COPD treatment standards.
Will Merck’s Ohtuvayre pricing strategy face EU pushback during HTA reviews?
Will EU payers push back on Merck’s Ohtuvayre pricing? Find out how HTA reviews may shape COPD access, margins, and the drug’s long-term European rollout.
Can fixed-dose combinations make Ohtuvayre Merck’s next billion-dollar respiratory franchise?
Can a fixed-dose combo turn Ohtuvayre into Merck’s next billion-dollar COPD franchise? Find out how lifecycle strategy may reshape respiratory care.
Can Merck turn Ohtuvayre into a global COPD blockbuster? A look at pricing, access, and lifecycle strategy
Can Merck scale Ohtuvayre into a global COPD blockbuster? Explore its pricing strategy, global access plans, and lifecycle ambitions in this in-depth analysis.
Merck to acquire Verona Pharma for $10bn, securing Ohtuvayre COPD therapy
Verona Pharma stock jumps 20% as Merck announces $10B acquisition to boost its COPD pipeline with first-in-class therapy Ohtuvayre. Read full analysis.
NeoGenomics appoints Merck oncology executive Dr. Marjorie Green to its board to advance leadership in precision diagnostics
NeoGenomics adds Merck oncology leader Dr. Marjorie Green to board, strengthening its precision diagnostics strategy and global pharmaceutical partnerships.
The oral biologics revolution: How macrocyclic peptides could reshape drug delivery
Macrocyclic peptides are revolutionizing oral biologics. Explore how Merck, Protagonist, and others are turning injectables into convenient, high-impact pills.